PE Ratio
45.99
₹2,531.50 -8.80 (-0.35%)
As on October 12, 2026
-8.52%
1 Y CAGR
48,386
CR
Market Cap
Company profile
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Price Chart
Fundamentals - Company Valuation
PB Ratio
0.12
Dividend Yield
2.06%
Sector PE
47.63
Sector ROE
11.70%
Sector Dividend Yield
0.46%
Financials
LIVE DATA FEED
Total Revenue (YTD)
₹38.2KCAGR 5-Year
+3.91%Peers & Comparison
SUNPHARMA
Sun Pharmaceutical Industries Ltd
Market cap: ₹4,41,477.63 Cr
DIVISLAB
Divi's Laboratories Ltd
Market cap: ₹2,41,576.41 Cr
TORNTPHARM
Torrent Pharmaceuticals Ltd
Market cap: ₹1,82,576.57 Cr
Missed the last rally? Don’t miss the next
Looking for AI-researched technical positive stocks?
Our AI-powered Analytical Portal finds the strongest technical positive stocks with actionable Buy & Sell opportunities.
Corporate Actions
Still Thinking? Not sure which stocks are right for you?
We help investors understand what to buy, when to buy, and why it makes sense for them.
customersupport@jarvisinvest.com
New Customers (Enquiry): +91 7208809638
Mon - Sat | 10:00 AM - 07:00 PM (Sunday Closed)
